STVN Stock Forecast 2025-2026
Distance to STVN Price Targets
STVN Price Momentum
10 Quality Stocks Worth Considering Now
Researching Stevanato Group (STVN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on STVN and similar high-potential opportunities.
Latest STVN Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, STVN has a bullish consensus with a median price target of $27.00 (ranging from $21.00 to $37.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $20.03, the median forecast implies a 34.8% upside. This outlook is supported by 7 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Paul Knight at Keybanc, projecting a 84.7% upside. Conversely, the most conservative target is provided by Timothy Daley at Wells Fargo, suggesting a 4.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STVN Analyst Ratings
STVN Price Target Range
Latest STVN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STVN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 7, 2025 | UBS | John Sourbeer | Neutral | Maintains | $23.50 |
| Dec 13, 2024 | Wolfe Research | Doug Schenkel | Outperform | Initiates | $28.00 |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Buy | Maintains | $26.00 |
| Dec 3, 2024 | Morgan Stanley | Tejas Savant | Equal-Weight | Assumes | $23.00 |
| Aug 7, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $28.00 |
| Jul 15, 2024 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $22.00 |
| Apr 22, 2024 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $30.00 |
| Mar 25, 2024 | Stephens & Co. | Jacob Johnson | Overweight | Reiterates | $38.00 |
| Nov 1, 2023 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $30.00 |
| Nov 1, 2023 | Jefferies | David Windley | Hold | Downgrade | $29.00 |
| Sep 26, 2023 | Stephens & Co. | Jacob Johnson | Overweight | Initiates | $33.00 |
| Sep 19, 2023 | CJS Securities | Larry Solow | Market Outperform | Initiates | $36.00 |
| Aug 30, 2023 | Keybanc | Paul Knight | Overweight | Maintains | $37.00 |
| Aug 24, 2023 | Morgan Stanley | Drew Ranieri | Equal-Weight | Downgrade | $34.00 |
| Jul 31, 2023 | Wells Fargo | Overweight | Maintains | $0.00 | |
| Jul 31, 2023 | Morgan Stanley | Overweight | Maintains | $0.00 | |
| Jul 17, 2023 | Morgan Stanley | Overweight | Reiterates | $0.00 | |
| Jun 26, 2023 | Morgan Stanley | Drew Ranieri | Overweight | Reiterates | $29.00 |
| Jun 20, 2023 | Morgan Stanley | Drew Ranieri | Overweight | Reiterates | $29.00 |
| Jun 16, 2023 | B of A Securities | Buy | Maintains | $0.00 |
Stevanato Group S.p.A. (STVN) Competitors
The following stocks are similar to Stevanato Group based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Stevanato Group S.p.A. (STVN) Financial Data
Stevanato Group S.p.A. has a market capitalization of $5.47B with a P/E ratio of 42.6x. The company generates $1.20B in trailing twelve-month revenue with a 10.7% profit margin.
Revenue growth is +3.1% quarter-over-quarter, while maintaining an operating margin of +20.3% and return on equity of +9.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Stevanato Group S.p.A. (STVN) Business Model
About Stevanato Group S.p.A.
Designs and produces drug containment solutions.
The company generates revenue by providing highly engineered glass primary packaging and integrated delivery systems for the pharmaceutical and healthcare industries. Their products are essential for the safe storage and administration of medications, particularly in the life sciences sector, where the reliability of drug delivery is critical.
Stevanato Group's innovations support various therapeutic areas, including oncology, diabetes, and infectious diseases. With a strong presence in the global market and headquarters in Italy, the company is well-positioned to meet the growing demand for effective healthcare solutions.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
5,521
CEO
Mr. Franco Stevanato
Country
Italy
IPO Year
2021
Website
www.stevanatogroup.comStevanato Group S.p.A. (STVN) Latest News & Analysis
Stevanato Group S.p.A. (NYSE: STVN) will present at the KeyBanc Capital Markets Healthcare Forum on March 18, 2025, at 3:00 p.m. ET, with a live webcast available.
Stevanato Group's participation in the KeyBanc Healthcare Forum signals potential visibility and investment interest, which could impact stock performance and market perception.
Stevanato's 2024 revenue reached €1.1 billion, exceeding expectations, driven by Biopharmaceutical and Diagnostic Solutions. Expansion investments aim to meet rising demand and provide downside protection.
Stevanato's revenue beat expectations, driven by strong biopharmaceutical demand. Facility expansions and strategic CAPEX provide growth potential and risk mitigation, appealing to investors.
Stevanato Group S.p.A. (NYSE: STVN) will hold its Q4 2024 Earnings Conference Call on March 6, 2025, at 8:30 AM ET, featuring key executives and analysts from major firms.
The upcoming earnings call for Stevanato Group provides insights into financial performance and strategic direction, influencing investor sentiment and stock valuation.
Stevanato Group (NYSE: STVN) reported Q4 2024 revenue of €330.6 million, up 3% year-over-year, driven by high-value solutions in drug delivery and diagnostic sectors.
Stevanato Group's revenue growth signals strong demand for its solutions in pharmaceuticals, which may enhance investor confidence and influence stock performance positively.
Stevanato Group (STVN) reported quarterly earnings of $0.20 per share, matching the Zacks Consensus Estimate and up from $0.19 per share year-over-year.
Stevanato Group's earnings meeting expectations signals stability and potential growth, while a year-over-year increase suggests improving performance, which may positively influence investor sentiment.
Stevanato Group to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 6, 2025
20 days agoStevanato Group S.p.A. (NYSE: STVN) will release its Q4 and fiscal year 2024 financial results on March 6, 2025, at 6:30 a.m. ET, followed by a conference call at 8:30 a.m. ET.
Stevanato Group's upcoming financial results announcement may influence stock performance and investor sentiment, providing insight into the company's growth and operational health.
Frequently Asked Questions About STVN Stock
What is Stevanato Group S.p.A.'s (STVN) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Stevanato Group S.p.A. (STVN) has a median price target of $27.00. The highest price target is $37.00 and the lowest is $21.00.
Is STVN stock a good investment in 2025?
According to current analyst ratings, STVN has 7 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $20.03. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STVN stock?
Wall Street analysts predict STVN stock could reach $27.00 in the next 12 months. This represents a 34.8% increase from the current price of $20.03. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Stevanato Group S.p.A.'s business model?
The company generates revenue by providing highly engineered glass primary packaging and integrated delivery systems for the pharmaceutical and healthcare industries. Their products are essential for the safe storage and administration of medications, particularly in the life sciences sector, where the reliability of drug delivery is critical.
What is the highest forecasted price for STVN Stevanato Group S.p.A.?
The highest price target for STVN is $37.00 from Paul Knight at Keybanc, which represents a 84.7% increase from the current price of $20.03.
What is the lowest forecasted price for STVN Stevanato Group S.p.A.?
The lowest price target for STVN is $21.00 from Timothy Daley at Wells Fargo, which represents a 4.8% increase from the current price of $20.03.
What is the overall STVN consensus from analysts for Stevanato Group S.p.A.?
The overall analyst consensus for STVN is bullish. Out of 12 Wall Street analysts, 7 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $27.00.
How accurate are STVN stock price projections?
Stock price projections, including those for Stevanato Group S.p.A., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
